Monica Galli

Summary

Country: Italy

Publications

  1. ncbi Interpretation and recommended testing for antiphospholipid antibodies
    Monica Galli
    Divisione di Ematologia, Ospedali Riuniti, Largo Barozzi 1, Bergamo, Italy
    Semin Thromb Hemost 38:348-52. 2012
  2. ncbi Phospholipid inhibitors. State of the Art
    M Galli
    Monica Galli, Divisione di Ematologia, Ospedali Riuniti, L go Barozzi, 1, 24128, Bergamo, Tel 035 26 94 92, Fax 035 26 61 64, E mail
    Hamostaseologie 31:243-50. 2011
  3. ncbi Clinical significance of different antiphospholipid antibodies in the WAPS (warfarin in the antiphospholipid syndrome) study
    Monica Galli
    Divisione di Ematologia, Ospedali Riuniti, Bergamo, Italy
    Blood 110:1178-83. 2007
  4. ncbi Feasibility and outcome of tandem stem cell autotransplants in multiple myeloma
    Monica Galli
    Divisione di Ematologia, Ospedali Riuniti, Bergamo, Italy
    Haematologica 90:1643-9. 2005
  5. ncbi Anti-prothrombin IgG from patients with anti-phospholipid antibodies inhibits the inactivation of factor Va by activated protein C
    Monica Galli
    Department of Haematology, Ospedali Riuniti, Bergamo, Italy
    Br J Haematol 129:240-7. 2005
  6. ncbi Antiphospholipid syndrome: clinical and diagnostic utility of laboratory tests
    Monica Galli
    Divisione di Ematologia, Ospedali Riuniti, Bergamo, Italy
    Semin Thromb Hemost 31:17-24. 2005
  7. ncbi Antiphospholipid syndrome: association between laboratory tests and clinical practice
    Monica Galli
    Division of Hematology, Ospedali Riuniti, Bergamo, Italy
    Pathophysiol Haemost Thromb 33:249-55. 2003
  8. ncbi Antiphospholipid antibodies and thrombosis: do test patterns identify the patients' risk?
    Monica Galli
    Divisione di Ematologia, Ospedali Riuniti, L go Barozzi, 1, 24128 Bergamo, Italy
    Thromb Res 114:597-601. 2004
  9. ncbi Antiphospholipid antibodies and pregnancy
    Monica Galli
    Department of Haematology, Ospedali Riuniti, Largo Barozzi 1, 24128 Bergamo, Italy
    Best Pract Res Clin Haematol 16:211-25. 2003
  10. ncbi Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature
    Monica Galli
    Division of Hematology, Ospedali Riuniti, Bergamo, Italy
    Blood 101:1827-32. 2003

Detail Information

Publications25

  1. ncbi Interpretation and recommended testing for antiphospholipid antibodies
    Monica Galli
    Divisione di Ematologia, Ospedali Riuniti, Largo Barozzi 1, Bergamo, Italy
    Semin Thromb Hemost 38:348-52. 2012
    ..Hopefully, this increasing knowledge will help improve diagnostic and treatment strategies for APS...
  2. ncbi Phospholipid inhibitors. State of the Art
    M Galli
    Monica Galli, Divisione di Ematologia, Ospedali Riuniti, L go Barozzi, 1, 24128, Bergamo, Tel 035 26 94 92, Fax 035 26 61 64, E mail
    Hamostaseologie 31:243-50. 2011
    ..Low molecular weight heparin (LMWH) with or without aspirin is recommended to reduce the rate of obstetrical complications of APS pregnant women...
  3. ncbi Clinical significance of different antiphospholipid antibodies in the WAPS (warfarin in the antiphospholipid syndrome) study
    Monica Galli
    Divisione di Ematologia, Ospedali Riuniti, Bergamo, Italy
    Blood 110:1178-83. 2007
    ..They also suggest that the measurement of aPT and aAnAV antibodies is useful in some selected situations and that there is little role for IgM antibody detection...
  4. ncbi Feasibility and outcome of tandem stem cell autotransplants in multiple myeloma
    Monica Galli
    Divisione di Ematologia, Ospedali Riuniti, Bergamo, Italy
    Haematologica 90:1643-9. 2005
    ....
  5. ncbi Anti-prothrombin IgG from patients with anti-phospholipid antibodies inhibits the inactivation of factor Va by activated protein C
    Monica Galli
    Department of Haematology, Ospedali Riuniti, Bergamo, Italy
    Br J Haematol 129:240-7. 2005
    ..Most, although not all, IgG containing anti-prothrombin antibodies inhibit the APC-catalysed FVa inactivation, which may contribute to the increased risk of thrombosis in patients with the anti-phospholipid syndrome...
  6. ncbi Antiphospholipid syndrome: clinical and diagnostic utility of laboratory tests
    Monica Galli
    Divisione di Ematologia, Ospedali Riuniti, Bergamo, Italy
    Semin Thromb Hemost 31:17-24. 2005
    ..Many efforts are currently being made to improve assay standardization and harmonization, which should help to clarify the clinical relevance of antiphospholipid antibodies...
  7. ncbi Antiphospholipid syndrome: association between laboratory tests and clinical practice
    Monica Galli
    Division of Hematology, Ospedali Riuniti, Bergamo, Italy
    Pathophysiol Haemost Thromb 33:249-55. 2003
    ..These results are mainly due to the still far from optimal standardization of the methods to detect the various antiphospholipid antibodies...
  8. ncbi Antiphospholipid antibodies and thrombosis: do test patterns identify the patients' risk?
    Monica Galli
    Divisione di Ematologia, Ospedali Riuniti, L go Barozzi, 1, 24128 Bergamo, Italy
    Thromb Res 114:597-601. 2004
    ..The role of the other antiphospholipid antibodies is less clear...
  9. ncbi Antiphospholipid antibodies and pregnancy
    Monica Galli
    Department of Haematology, Ospedali Riuniti, Largo Barozzi 1, 24128 Bergamo, Italy
    Best Pract Res Clin Haematol 16:211-25. 2003
    ..However, there is still an excessive frequency of maternal and/or fetal complications, indicating the necessity of a better calibration of the dosage, duration and timing of administration of heparin treatment...
  10. ncbi Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature
    Monica Galli
    Division of Hematology, Ospedali Riuniti, Bergamo, Italy
    Blood 101:1827-32. 2003
    ..However, to take full advantage of the conclusions provided by the available evidence, there is an urgent need to harmonize investigational methods...
  11. ncbi Antiphospholipid syndrome: definition and treatment
    Monica Galli
    Department of Haematology, Ospedali Riuniti, Bergamo, Italy
    Semin Thromb Hemost 29:195-204. 2003
    ....
  12. ncbi Anti-beta 2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome
    Monica Galli
    Department of Hematology, Ospedali Riuniti, Largo Barozzi 1, 24128 Bergamo, Italy
    Blood 102:2717-23. 2003
  13. ncbi Antiphospholipid antibodies and thrombosis: strength of association
    Monica Galli
    Department of Hematology, Ospedali Riuniti, Largo Barozzi 1, Bergamo 24128, Italy
    Hematol J 4:180-6. 2003
    ..Upon treatment, the live birth rate increases from 0-40% to 70-80%...
  14. ncbi Anti-beta2-glycoprotein I and anti-prothrombin antibodies in antiphospholipid-negative patients with thrombosis: a case control study
    Sara Previtali
    Department of Hematology, Ospedali Riuniti, Bergamo, Italy
    Thromb Haemost 88:729-32. 2002
    ..Their measurement, therefore, is not warranted in the laboratory screening of patients with arterial and/or venous thrombosis...
  15. ncbi Clinical utility of laboratory tests used to identify antiphospholipid antibodies and to diagnose the antiphospholipid syndrome
    Monica Galli
    Department of Hematology, Ospedali Riuniti, Bergamo, Italy
    Semin Thromb Hemost 34:329-34. 2008
    ..This should also help in simplifying the laboratory workup of patients being investigated for APS...
  16. ncbi Antiphospholipid antibodies in lymphoma: prevalence and clinical significance
    Simona Pusterla
    Divisione di Ematologia, Ospedali Riuniti, Bergamo, Italy
    Hematol J 5:341-6. 2004
    ..In conclusion, antiphospholipid antibodies are associated with lymphomas. Their determination is useful to identify patients at high risk to develop thrombotic complications, but not to predict treatment outcome or disease prognosis...
  17. ncbi Negative selection of peripheral blood stem cells to support a tandem autologous transplantation programme in multiple myeloma
    Anna Maria Barbui
    Divisione di Ematologia, Radioterapia and Centro Trasfusionale, Ospedali Riuniti, Bergamo, Italy
    Br J Haematol 116:202-10. 2002
    ..This suggests that autologous transplantation using efficiently purged PBSCs can be performed safely, but confirms the need for innovative protocols for MRD eradication in vivo...
  18. ncbi A phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma
    Monica Galli
    Div of Hematology, Ospedali Riuniti, Largo Barozzi, 1, 24128, Bergamo, Italy
    Ann Hematol 89:185-90. 2010
    ..In conclusion, when given at a dose of 100 mg twice daily alone or combined with dexamethasone, ITF2357 proved tolerable but showed a modest clinical benefit in advanced MM...
  19. ncbi Extramedullary intracranial localization of multiple myeloma and treatment with novel agents: a retrospective survey of 50 patients
    Alessandro Gozzetti
    Division of Hematology, Azienda Ospedaliera Universitaria Senese, Policlinico Santa Maria alle Scotte, Siena, Italy
    Cancer 118:1574-84. 2012
    ..Intracranial involvement in multiple myeloma is extremely rare. The effect of new drugs (eg, thalidomide, bortezomib, lenalidomide) with respect to old drugs (eg, alkylators, steroids) has not been reported...
  20. ncbi Toll-like receptor and antiphospholipid mediated thrombosis: in vivo studies
    Silvia S Pierangeli
    Antiphospholipid Standardization Laboratory, Division of Rheumatology, Department of Internal Medicine, University of Texas Medical Branch, Galveston, Texas 77555 1165, USA
    Ann Rheum Dis 66:1327-33. 2007
    ....
  21. ncbi Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial
    Antonio Palumbo
    Divisione di Ematologia dell Universita di Torino, Azienda Ospedaliera S Giovanni Battista, 10126 Torino, Italy
    Lancet 367:825-31. 2006
    ..This multicentre randomised trial compared oral MP plus thalidomide (MPT) with MP alone in patients aged 60-85 years...
  22. ncbi Kinetics of prothrombin-mediated binding of lupus anticoagulant antibodies to phosphatidylserine-containing phospholipid membranes: an ellipsometric study
    George M Willems
    Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, The Netherlands
    Biochemistry 41:14357-63. 2002
    ..The kinetics of adsorption and desorption indicate that divalent binding of LA IgG to prothrombin at the lipid membrane occurs...
  23. ncbi Recombinant human erythropoietin and the risk of thrombosis in patients receiving thalidomide for multiple myeloma
    Monica Galli
    Haematologica 89:1141-2. 2004
    ..1%; annual rate 7.25%), and another 14 events occurred in patients not on erythropoietin (9.3%; 7.56%). Thus, erythropoietin would seem not to increase the risk of thrombosis of myeloma patients receiving thalidomide...
  24. ncbi Antibodies to tissue-type plasminogen activator (tPA) in patients with antiphospholipid syndrome: evidence of interaction between the antibodies and the catalytic domain of tPA in 2 patients
    Massimo Cugno
    Department of Internal Medicine and Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, IRCCS Maggiore Hospital and University of Milan, Via Pace 15, 20122 Milano, Italy
    Blood 103:2121-6. 2004
    ..Our data indicate that anti-tPA antibodies specifically interacting with the catalytic domain of tPA can be found in patients with APS, representing a possible cause of hypofibrinolysis...
  25. ncbi Improving management of pregnancy in antiphospholipid antibody-positive women
    Monica Galli
    J Rheumatol 33:2108-9. 2006